Atul Chawla, MD
Interventional Cardiology · Des Moines, IANPI 1700868080
Payments from drug & device makers
Across 604 payments — averaging $802.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$434K
- Abbott$28K
- Boston Scientific$13K
- Bayer$4K
- Edwards Lifesciences$2K
- Philips North America LLC$1K
- plus $3K from 18 others
What the payments were for
- Speaking & faculty fees$41,38153%
- Travel & lodging$24,97732%
- Food & beverage$11,49615%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 310 | $433,910 |
| Abbott | 115 | $27,708 |
| Boston Scientific | 28 | $12,782 |
| Bayer | 7 | $3,883 |
| Edwards Lifesciences | 39 | $2,473 |
| Philips North America LLC | 21 | $1,002 |
| Shockwave Medical, Inc | 15 | $994 |
| Abiomed | 8 | $468 |
| Cardiovascular Systems Inc. | 6 | $231 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $219 |
| Teleflex LLC | 5 | $193 |
| E.r. Squibb & Sons, L.L.C. | 8 | $162 |
| Cardiva Medical, Inc. | 6 | $154 |
| Asahi Intecc USA, Inc. | 1 | $147 |
| AstraZeneca | 3 | $138 |
| Novartis | 6 | $128 |
| Pfizer | 5 | $95 |
| Heartflow, Inc. | 3 | $93 |
| Chiesi USA, Inc. | 4 | $48 |
| Penumbra, Inc. | 1 | $21 |
| AbbVie | 1 | $21 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $17 |
| Livanova USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$45,794
- COREVALVE EVOLUT R$13,013
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,547
- GENERAL - THERAPIES$1,294
- WATCHMAN Access System$1,179
- Xience V coronary stent system$1,052
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$743
- PORTICO$265
- Impella$253
- APOLLOTM$196
- Ultreon$177
- Diamondback Coronary$169
- CardioMEMS HF System$161
- Fortify Assura, Ellipse ICD$151
- PERIPHERAL VASCULAR$147
- Tri-Ad$141
- Xience Sierra Coronary Stent System$124
- Vascular Lithotripsy$116
- IGT Devices Und$112
- BRILINTA$103
How this compares
$484,919 in reported general payments places this provider in the 95th percentile of 64 interventional cardiology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 116 | $78,523 |
| BrilintaTicagrelor | 38 | $17,652 |
| XareltoRivaroxaban | 19 | $13,450 |
| LivaloPitavastatin Calcium | 13 | $5,181 |
| Metoprolol Succinate | 163 | $1,289 |
| Enoxaparin Sodium | 13 | $1,161 |
| Triamterene | 12 | $1,059 |
| ClopidogrelClopidogrel Bisulfate | 141 | $733 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 48 | $575 |
| Losartan Potassium | 54 | $373 |
| Rosuvastatin Calcium | 51 | $346 |
| Atorvastatin Calcium | 76 | $344 |
| Potassium Chloride | 20 | $328 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 29 | $244 |
| Carvedilol | 47 | $227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $95 | $78,523116 claims |
| AstraZenecaBrilinta | $138 | $17,65238 claims |
| Johnson & JohnsonXarelto | $17 | $13,45019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 64 interventional cardiology providers in Iowa.
Other interventional cardiology in Des Moines
- David McAllisterDes Moines$149K
- Daniel ShivapourDes Moines$135K
- Abdulrahman AbdulbakiDes Moines$43K
- Musab AlqasrawiDes Moines$6K
- Ravinder DerveshDes Moines$3K
- Hamza OglatDes Moines$924
- Aaron FromDes Moines$793
- Martin AronowDes Moines$232
- Nicolas ShammasDavenport$4.8M
- Phillip HorwitzIowa City$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.